Fresh off a name change, the company last week introduced a monitoring platform for new SARS-CoV-2 variants that alerts diagnostic test makers to potential problems.
The University of Washington spinout, formerly called Split Biosciences, has received orders for its new whole-transcriptome kit from 50 early-access partners.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
